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Habitual Sleep Duration and Predicted 10-Year Cardiovascular Risk
Using the Pooled Cohort Risk Equations Among US Adults
Earl S. Ford, MD, MPH
Background-—The association between sleep duration and predicted cardiovascular risk has been poorly characterized. The
objective of this study was to examine the association between self-reported sleep duration and predicted 10-year cardiovascular
risk among US adults.
Methods and Results-—Data from 7690 men and nonpregnant women who were aged 40 to 79 years, who were free of self-
reported heart disease and stroke, and who participated in a National Health and Nutrition Examination Survey from 2005 to 2012
were analyzed. Sleep duration was self-reported. Predicted 10-year cardiovascular risk was calculated using the pooled cohort
equations. Among the included participants, 13.1% reported sleeping ≤5 hours, 24.4% reported sleeping 6 hours, 31.9% reported
sleeping 7 hours, 25.2% reported sleeping 8 hours, 4.0% reported sleeping 9 hours, and 1.3% reported sleeping ≥10 hours. After
adjustment for covariates, geometric mean–predicted 10-year cardiovascular risk was 4.0%, 3.6%, 3.4%, 3.5%, 3.7%, and 3.7%
among participants who reported sleeping ≤5, 6, 7, 8, 9, and ≥10 hours per night, respectively (PWald chi-square<0.001). The age-
adjusted percentages of predicted cardiovascular risk ≥20% for the 6 intervals of sleep duration were 14.5%, 11.9%, 11.0%, 11.4%,
11.8%, and 16.3% (PWald chi-square=0.022). After maximal adjustment, however, sleep duration was not significantly associated with
cardiovascular risk ≥20% (PWald chi-square=0.698).
Conclusions-—Mean-predicted 10-year cardiovascular risk was lowest among adults who reported sleeping 7 hours per night and
increased as participants reported sleeping fewer and more hours. ( J Am Heart Assoc. 2014;3:e001454 doi: 10.1161/
JAHA.114.001454)
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T he possible benefits of adequate sleep in maintainingcardiovascular health are increasingly being recognized.
Because cardiovascular disease continues to be a leading
cause of morbidity and mortality in the United States,
understanding how the many aspects of sleep health relate
to cardiovascular disease can help formulate new approaches
to the prevention and control of this disease. In 2011, a meta-
analysis of prospective studies of sleep duration and cardio-
vascular disease showed an increased risk for coronary heart
disease and stroke with both short and long duration of sleep.1
Although studies have examined associations between
sleep duration and various cardiovascular risk factors
included in the risk equations,2–13 an aspect of the study of
sleep duration and cardiovascular health that has been
overlooked is the relationship between sleep duration and
predicted cardiovascular risk. Beginning with the Framingham
risk equations, a succession of risk scores to assess future
cardiovascular risk—typically projecting 10 years ahead—
have been introduced into clinical practice. Recently, a new
set of cardiovascular risk equations has been introduced in
the United States.14 Because the potential association
between sleep duration and predicted cardiovascular risk
remains ill defined, the objective of this study was to examine
how 10-year predicted cardiovascular risk varies as a function
of sleep duration among adults in the United States.
Methods
Four 2-year cycles of data from the National Health and
Nutrition Examination Survey (NHANES) 2005–2012 were
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included in this analysis.15 Using a multistage, stratified
sampling design, every 2-year cycle includes a national
sample representative of the civilian, noninstitutionalized US
population. After providing informed consent, participants
were interviewed in their homes. Those who attended a
mobile examination center completed additional question-
naires, had various examinations, and provided a blood
sample. Interview and examination response rates for each 2-
year cycle exceeded 70%. The surveys received approval from
the National Center for Health Statistics Research ethics
review board, and participants in the surveys provided
informed consent.
Of the 12 785 men and nonpregnant women aged 40 to
79 years who attended the mobile examination center, 11 023
participants were free of self-reported cardiovascular disease.
Predicted cardiovascular risk could be calculated for 9988 of
these participants, and 11 007 participants provided informa-
tion about their sleep duration. After excluding participants
who were using cholesterol-lowering medications, the sample
size was reduced to 8675 participants, of whom 7690 with
complete data for all study variables were included in the
analyses. The participants included 3746 men (48.7%), 3944
women (51.3%), 3487 white participants (45.3%), 1624 black
participants (21.1%), 1302 Mexican American participants
(16.9%), and 1277 of another race or ethnicity (16.6%). The
mean age of this sample was 54.6 years.
Predicted 10-year cardiovascular risk for adults aged 40 to
79 years was calculated using the pooled cohort equations
for estimation of 10-year risk for atherosclerotic cardiovas-
cular disease developed by the American College of Cardiol-
ogy/American Heart Association (ACC/AHA) Task Force on
Practice Guidelines.14 Separate equations for white and black
men and women were developed and included the following
set of variables: age, concentrations of total cholesterol and
high-density lipoprotein cholesterol, treated and untreated
systolic blood pressure, diabetes status, and smoking status.
Participants who reported that they had ever been told by a
doctor or other health professional that they had congestive
heart failure, coronary heart disease, angina, heart attack, or
stroke were excluded from the analyses. Participants with
risks of <7.5% and ≥20% were considered to be at low and
high risk, respectively, for future cardiovascular events.16
Concentrations of total cholesterol and concentrations of
high-density lipoprotein cholesterol, after precipitation with
magnesium and dextran sulfate, were measured with an
enzymatic method on Hitachi 717 and 912 analyzers (Hitachi
Global Storage Technologies) during the period 2005–2006
and on Roche Modular P chemistry analyzers (Roche
Diagnostics) during 2007–2012. Systolic blood pressure
measurements consisted of the average of the last 2
measurements of blood pressure for participants who had 3
measurements, the last measurement for participants with
only 2 measurements, and the only measurement for
participants who had 1 measurement. Blood pressure treat-
ment status was determined from the question, “Are you now
taking prescribed medicine?” Participants were considered to
have diabetes if they responded affirmatively to the question,
“Have you ever been told by a doctor or health professional
you have diabetes or sugar diabetes?” or if they had a
concentration of glycated hemoglobin (HbA1c) ≥6.5%. Con-
centrations of HbA1c were measured by high-performance
liquid chromatography on a Tosoh A1c 2.2 Plus glycohemo-
globin analyzer (2005–2006), a Tosoh G7 HPLC analyzer
(2007–2012), and a Tosoh G8 HPLC analyzer (2011–2012)
(Tosoh Medics, Inc). Participants who reported that they had
smoked ≥100 cigarettes during their lifetime and were still
smoking were defined as being current smokers. Those who
had smoked ≥100 cigarettes during their lifetime but had
stopped were defined as being former smokers. Participants
who had smoked <100 cigarettes during their lifetime were
defined as having never smoked.
Sleep duration was assessed with the question, “How
much sleep do you usually get at night on weekdays or
workdays?” Answers ranged from 1 hour to 12 hours per
night in whole hours. Answers of >12 hours were available
only as a category of ≥12 hours. To examine the shape of the
association between sleep duration and cardiovascular risk in
as much detail as sample size allowed, the following 6
categories of sleeping duration were established for the
analyses: ≤5, 6, 7, 8, 9, and ≥10 hours per night.
The following covariates were included in the analyses:
age, sex, race or ethnicity (white, black, Mexican American,
and other), educational status (less than high school graduate,
high school graduate or equivalent, more than high school),
leisure-time physical activity, body mass index, and histories
of chronic obstructive pulmonary disease, arthritis, liver
disease, thyroid problems, cancer, and sleep disorders. For
the years 2005 and 2006, leisure-time physical activity as a
weekly metabolic equivalent (MET) -hours index was esti-
mated by summing the product of weekly time spent in each
activity multiplied by the MET value for that activity. One MET
is the energy expenditure of 1 kcal/kg body weight per
hour. Owing to changes in the physical activity questionnaire
for the years 2007–2012, weekly MET-hours for moderate
and vigorous activities were estimated from questions that
asked participants about their participation in moderate and
vigorous activities, the number of days per week they engaged
in these activities, and the number of minutes engaged in
these activities on a typical day. Body mass index was
calculated from measured height and weight. Participants
who responded that they still had chronic bronchitis or ever
had emphysema were defined as having chronic obstructive
pulmonary disease. Participants with arthritis, liver disease,
thyroid problems, and cancer were identified from the
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questions, “Has a doctor or other health professional ever told
you that you had . . . arthritis/any kind of liver condition/
thyroid problem/cancer or a malignancy of any kind?” The
presence of a sleep disorder was inferred from the question,
“Have you ever been told by a doctor or other health
professional that you have a sleep disorder?”
The analyses, which included 8 years of pooled data,
were limited to men and nonpregnant women who were
aged 40 to 79 years and free of self-reported cardiovascular
disease. Participants who reported taking prescribed medi-
cine to lower blood cholesterol were excluded. Predicted
cardiovascular risk was log-transformed. The statistical
significance of the associations between continuous vari-
ables and categories of sleep duration was tested with linear
regression analysis. Statistical significance of associations
between dichotomous variables and categories of sleep
duration was tested with log-linear analysis. Least-squares
adjusted mean-predicted cardiovascular risk was calculated
by using analysis of covariance. Analyses were conducted
with SUDAAN (RTI International) to account for the complex
survey design, and sampling weights were used to calculate
estimates (means, percentages, regression coefficients, and
prevalence ratios). Statistical significance was defined as
P<0.05.
Table 1. Unadjusted Mean or Percent (SE) of Selected Factors Among Adults Aged 40 to 79 Years Who Were Free of Self-
Reported Cardiovascular Disease by Sleep Duration, National Health and Nutrition Examination Survey 2005–2012
Habitual Sleep Duration (Hours per Night)
PWald F or chi-square≤5 6 7 8 9 ≥10
n 1230 1921 2174 1934 304 127 ―
Age, y 52.2 (0.3) 52.8 (0.3) 53.2 (0.3) 54.0 (0.4) 55.1 (0.9) 55.2 (1.2) <0.001
Men, % 47.8 (1.8) 53.1 (1.6) 47.3 (1.3) 43.5 (1.7) 34.6 (3.2) 35.8 (5.5) <0.001
White race, % 59.3 (2.9) 70.4 (2.0) 79.4 (1.4) 75.9 (1.8) 80.6 (2.5) 70.8 (4.6) <0.001
High school graduate or higher, % 77.9 (1.6) 83.8 (1.2) 86.1 (0.9) 83.8 (1.0) 79.4 (2.7) 71.1 (4.3) <0.001
Total cholesterol, mg/dL 209.9 (1.5) 207.5 (1.4) 209.0 (0.9) 211.6 (1.5) 213.2 (3.1) 204.8 (3.9) 0.136
High-density lipoprotein cholesterol, mg/dL 54.2 (0.7) 53.4 (0.6) 55.4 (0.4) 56.2 (0.6) 56.0 (1.0) 55.4 (2.2) 0.011
Systolic blood pressure, mm Hg 124.9 (0.6) 123.2 (0.5) 122.4 (0.5) 123.3 (0.5) 123.7 (1.2) 123.9 (1.6) 0.064
HbA1c, % 5.7 (<0.1) 5.6 (<0.1) 5.5 (<0.1) 5.6 (<0.1) 5.6 (<0.1) 5.6 (0.1) <0.001
Leisure-time physical activity, MET-h/week 8.3 (0.6) 13.2 (0.9) 14.7 (0.7) 14.4 (0.7) 13.2 (2.5) 12.0 (3.8) <0.001
Body mass index, kg/m2 29.5 (0.3) 29.1 (0.2) 28.4 (0.1) 28.3 (0.2) 28.9 (0.5) 28.9 (0.9) 0.008
Current smoker, % 31.9 (1.9) 22.3 (1.3) 16.9 (1.0) 16.9 (1.1) 24.7 (3.5) 37.5 (5.4) <0.001
Current use of antihypertensive medications, % 22.4 (1.4) 21.3 (1.0) 19.8 (1.0) 20.3 (1.1) 17.8 (2.7) 19.3 (3.8) 0.313
Diabetes, % 10.6 (1.2) 10.3 (0.9) 6.4 (0.6) 9.4 (0.7) 7.1 (1.4) 11.3 (3.0) <0.001
Medical history
Chronic obstructive pulmonary disease, % 6.4 (1.0) 3.9 (0.7) 2.0 (0.4) 3.3 (0.5) 2.5 (0.8) 8.0 (3.0) <0.001
Arthritis, % 38.6 (2.0) 26.4 (1.8) 25.9 (1.2) 26.9 (1.4) 23.4 (2.6) 41.1 (5.4) <0.001
Thyroid, % 9.9 (0.9) 9.4 (0.9) 12.2 (0.9) 12.1 (1.0) 10.7 (2.4) 14.5 (3.0) 0.095
Liver, % 5.0 (0.9) 4.3 (0.7) 3.4 (0.5) 4.1 (0.5) 3.4 (1.3) 7.9 (3.2) 0.385
Cancer, % 8.1 (0.9) 8.2 (0.8) 8.9 (0.6) 11.4 (1.1) 12.8 (2.2) 10.1 (3.7) 0.073
Sleep disorder, % 16.7 (1.5) 7.3 (0.8) 6.7 (0.7) 6.1 (0.9) 10.5 (2.9) 9.0 (3.0) <0.001
Mean 10-year risk, % 7.1 (0.2) 7.0 (0.3) 6.2 (0.2) 7.4 (0.3) 8.2 (0.7) 9.2 (1.1) <0.001
Mean 10-year risk, %* 4.0 (0.2) 3.8 (0.2) 3.2 (0.1) 3.5 (0.2) 3.8 (0.4) 4.4 (0.7) 0.004
10-year risk, %
<7.5 70.2 (1.9) 69.0 (1.7) 74.0 (1.2) 69.6 (1.5) 63.9 (3.8) 62.0 (6.0) ―
7.5 to <20 22.5 (1.8) 23.5 (1.4) 19.8 (0.9) 21.3 (1.1) 24.8 (3.1) 21.4 (4.3) ―
≥20 7.2 (0.8) 7.5 (0.8) 6.2 (0.6) 9.1 (0.8) 11.4 (1.7) 16.6 (3.8) <0.001
MET-h indicates metabologic equivalent hours. HbA1c indicates glycated hemoglobin.
*Geometric mean.
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Among the included participants, 13.1% (SE 0.6) reported
sleeping ≤5 hours, 24.4% (SE 0.6) reported sleeping 6 hours,
31.9% (SE 0.7) reported sleeping 7 hours, 25.2% (SE 0.6)
reported sleeping 8 hours, 4.0% (SE 0.3) reported sleeping
9 hours, and 1.3% (SE 0.1) reported sleeping ≥10 hours.
Mean-predicted cardiovascular risk was 6.9% (SE 0.1).
Furthermore, 70.6% (SE 0.7) of participants had a cardiovas-
cular risk <7.5%, 21.7% (SE 0.6) had a risk 7.5% to <20%, and
7.7% (SE 0.3) had a risk ≥20%.
Mean age increased by 3 years across categories of sleep
duration (Table 1). With the exception of mean concentrations
of total cholesterol and the percentage of participants who
reported using antihypertensive medications, the other
cardiovascular disease risk factors varied significantly across
categories of sleep duration.
Crude mean-predicted 10-year cardiovascular risk showed
a curvilinear association with sleep duration with the lowest
mean risk occurring among those who reported sleeping
7 hours per night (6.2%) and the highest risk among those
who reported sleeping ≥10 hours per night (9.2%) (PWald F
test<0.001) (Table 1). Because mean age varied considerably
by sleep duration and because age is a powerful determinant
of risk, age-adjusted risk was also calculated. Although the
nonlinearity of the relationship remained after age-adjustment
(PWald F test<0.001), the differences in cardiovascular risk
among sleep-duration categories were attenuated. The max-
imally adjusted geometric mean-predicted 10-year cardiovas-
cular risk was 4.0%, 3.6%, 3.4%, 3.5%, 3.7%, and 3.7% among
participants who reported sleeping ≤5, 6, 7, 8, 9, and
≥10 hours per night, respectively (PWald F test<0.001)
(Table 2). Using 7 hours as the reference category, the
differences in mean cardiovascular risk between ≤5 and
6 hours and the referent category were statistically signifi-
cant.
The unadjusted percentages of adults with a predicted 10-
year cardiovascular risk ≥20% were 7.2%, 7.5%, 6.2%, 9.1%,
11.4%, and 16.6% among participants who reported sleeping
≤5, 6, 7, 8, 9, and ≥10 hours per night, respectively (Table 3).
Direct age adjustment modified these estimates substantially.
In unadjusted models, participants who slept 8, 9, and
≥10 hours all had elevated prevalence ratios compared with
participants who slept 7 hours (Table 3). After maximal
adjustment, sleep duration was no longer significantly asso-
ciated with cardiovascular risk ≥20% (PWald chi-square=0.698).
Table 2. Geometric Mean Unadjusted and Adjusted Predicted 10-Year Cardiovascular Risk Among Adults Aged 40 to 79 Years
Who Were Free of Self-Reported Cardiovascular Disease by Sleep Duration, National Health and Nutrition Examination Survey
2005–2012
Habitual Sleep Duration (Hours per Night)
PWald F≤5 6 7 8 9 ≥10
n 1230 1921 2174 1934 304 127 ―
Model 1 4.0 (0.2) 3.8 (0.2) 3.2 (0.1) 3.5 (0.2) 3.8 (0.4) 4.4 (0.7) 0.004
Model 2 4.4 (0.1) 3.9 (0.1) 3.2 (0.1) 3.3 (0.1) 3.2 (0.2) 3.7 (0.4) <0.001
Model 3 4.0 (0.1) 3.6 (0.1) 3.4 (0.0) 3.5 (0.1) 3.7 (0.2) 3.7 (0.4) <0.001
Model 4 3.5 (0.1) 3.5 (0.1) 3.4 (0.1) 3.7 (0.1) 4.4 (0.4) 4.0 (0.5) 0.047
Men
n 606 992 1043 923 123 59 ―
Model 1 6.2 (0.3) 5.8 (0.3) 5.3 (0.2) 6.1 (0.3) 8.2 (1.0) 7.8 (1.5) 0.004
Model 2 6.8 (0.3) 6.1 (0.2) 5.3 (0.1) 5.8 (0.2) 6.2 (0.5) 6.0 (0.5) <0.001
Model 3 6.3 (0.3) 6.0 (0.2) 5.5 (0.1) 5.9 (0.2) 6.1 (0.4) 5.5 (0.5) 0.060
Model 4 5.5 (0.3) 5.8 (0.3) 5.5 (0.2) 6.3 (0.3) 8.2 (1.0) 6.6 (1.1) 0.004
Women
n 624 929 1131 1011 181 68 ―
Model 1 2.7 (0.1) 2.3 (0.1) 2.1 (0.1) 2.3 (0.1) 2.5 (0.3) 3.2 (0.7) 0.015
Model 2 3.0 (0.2) 2.3 (0.1) 2.1 (0.1) 2.1 (0.1) 2.4 (0.1) 2.8 (0.4) <0.001
Model 3 2.7 (0.1) 2.3 (0.1) 2.2 (0.0) 2.2 (0.1) 2.4 (0.1) 2.6 (0.3) 0.021
Model 4 2.3 (0.1) 2.3 (0.1) 2.2 (0.1) 2.3 (0.1) 2.7 (0.3) 2.5 (0.4) 0.742
Model 1 is unadjusted. Model 2 is adjusted for age. Model 3 is adjusted for age; sex (except sex-specific models); race or ethnicity; educational status; leisure-time physical activity; body
mass index; and histories of arthritis, cancer, chronic obstructive pulmonary disease, liver condition, thyroid problems, and sleep disorders. Model 4 is adjusted for all variables in Model 3
except age.
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Results for the maximally adjusted models for men and
women did not differ statistically (P interaction=0.100).
The unadjusted percentages of adults with a predicted 10-
year cardiovascular risk<7.5%were 70.2%, 69.0%, 74.0%, 69.6%,
63.9%, and 62.0% among participants who reported sleeping ≤5,
6, 7, 8, 9, and ≥10 hours per night, respectively (Table 4). In the
maximally adjusted model, sleep duration remained significantly
associated with cardiovascular risk <7.5%, and participants who
reported sleeping 9 hours were less likely to have a risk <7.5%
than participants who slept 7 hours. The associations between
sleep duration and risk <7.5% did not differ significantly between
men and women (Pinteraction=0.537).
Table 3. Prevalence (SE) of Predicted 10-Year Cardiovascular Risk ≥20% and Prevalence Ratios (95% CI) for Associations of
Between Sleep Duration and Cardiovascular Risk Among Adults Aged 40 to 79 Years Who Were Free of Self-Reported
Cardiovascular Disease, National Health and Nutrition Examination Survey 2005–2012
Habitual Sleep Duration (Hours per Night)
PWald
chi-square≤5 6 7 8 9 ≥10
Total
n 1230 1921 2174 1934 304 127
Prevalence,
unadjusted, %
7.2 (0.8) 7.5 (0.8) 6.2 (0.6) 9.1 (0.8) 11.4 (1.7) 16.6 (3.8) ―
Prevalence,
age-adjusted, %
14.5 (1.1) 11.9 (0.8) 11.0
(0.6)
11.4 (0.6) 11.8 (1.4) 16.3 (2.8) ―
Prevalence ratios
Model 1 1.17 (0.85 to 1.61) 1.21 (0.91 to 1.61) 1.00 1.48 (1.14 to 1.91) 1.84 (1.29 to 2.61) 2.67 (1.68 to 4.24) <0.001
Model 2 1.46 (1.14 to 1.88) 1.25 (1.00 to 1.58) 1.00 1.14 (0.95 to 1.37) 1.11 (0.84 to 1.47) 1.44 (1.03 to 2.02) 0.022
Model 3 1.23 (0.96 to 1.59) 1.13 (0.91 to 1.41) 1.00 1.08 (0.90 to 1.29) 1.06 (0.84 to 1.34) 1.21 (0.84 to 1.72) 0.698
Model 4 0.93 (0.67 to 1.28) 1.09 (0.84 to 1.40) 1.00 1.44 (1.12 to 1.83) 1.81 (1.31 to 2.49) 1.90 (1.22 to 2.97) <0.001
Men
n 606 992 1043 923 123 59
Prevalence,
unadjusted, %
8.1 (1.1) 9.1 (1.3) 8.9 (1.0) 13.1 (1.3) 19.8 (3.3) 25.2 (6.1) ―
Prevalence,
age-adjusted, %
17.3 (1.3) 17.1 (1.3) 16.3
(0.9)
17.3 (1.2) 17.2 (1.9) 24.0 (4.2) ―
Prevalence ratios
Model 1 0.91 (0.64 to 1.30) 1.03 (0.71 to 1.49) 1.00 1.48 (1.08 to 2.03) 2.24 (1.56 to 3.21) 2.84 (1.72 to 4.69) <0.001
Model 2 1.14 (0.86 to 1.52) 1.16 (0.83 to 1.63) 1.00 1.10 (0.85 to 1.44) 1.12 (0.85 to 1.48) 1.47 (0.88 to 2.46) 0.772
Model 3 1.01 (0.77 to 1.33) 1.10 (0.79 to 1.53) 1.00 1.04 (0.79 to 1.36) 1.03 (0.77 to 1.38) 1.22 (0.75 to 1.99) 0.960
Model 4 0.80 (0.57 to 1.13) 1.01 (0.72 to 1.43) 1.00 1.45 (1.06 to 1.97) 2.06 (1.46 to 2.93) 2.04 (1.17 to 3.55) <0.001
Women
n 624 929 1131 1011 181 68
Prevalence,
unadjusted, %
6.4 (1.2) 5.6 (0.7) 3.8 (0.4) 6.1 (0.7) 6.9 (1.9) 11.7 (4.2) ―
Prevalence,
age-adjusted, %
12.4 (1.7) 7.8 (0.8) 7.0 (0.7) 7.4 (0.6) 8.2 (1.7) 10.2 (2.4) ―
Prevalence ratios
Model 1 1.69 (1.05 to 2.72) 1.48 (1.06 to 2.07) 1.00 1.60 (1.19 to 2.15) 1.81 (0.98 to 3.35) 3.08 (1.50 to 6.33) 0.001
Model 2 2.19 (1.52 to 3.15) 1.39 (1.12 to 1.72) 1.00 1.29 (1.02 to 1.62) 1.24 (0.80 to 1.91) 1.67 (1.06 to 2.64) <0.001
Model 3 1.70 (1.14 to 2.52) 1.21 (0.99 to 1.47) 1.00 1.22 (0.98 to 1.53) 1.13 (0.71 to 1.79) 1.21 (0.71 to 2.08) 0.110
Model 4 1.16 (0.69 to 1.97) 1.28 (0.95 to 1.73) 1.00 1.42 (1.05 to 1.92) 1.61 (0.92 to 2.81) 1.82 (0.88 to 3.76) 0.037
Model 1 is unadjusted. Model 2 is adjusted for age. Model 3 is adjusted for age; sex (except sex-specific models); race or ethnicity; educational status; leisure-time physical activity;
body mass index; and histories of arthritis, cancer, chronic obstructive pulmonary disease, liver condition, thyroid problems, and sleep disorders. Model 4 is adjusted for all variables
in Model 3 except age.
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The present results are the first to describe associations
between self-reported sleep duration and predicted 10-year
cardiovascular risk in a nationally representative sample of
adults in the United States and thus provide novel evidence of
the links between sleep duration and cardiovascular health.
Based on the recently introduced ACC/AHA pooled cohort
Table 4. Prevalence (SE) of Predicted 10-Year Cardiovascular Risk <7.5% and Prevalence Ratios (95% CI) for Associations of
Between Sleep Duration and Cardiovascular Risk Among Adults Aged 40 to 79 Years Who Were Free of Self-Reported
Cardiovascular Disease, National Health and Nutrition Examination Survey 2005–2012
Habitual Sleep Duration (Hours per Night)
PWald chi-
square≤5 6 7 8 9 ≥10
Total
n 1230 1921 2174 1934 304 127
Prevalence,
unadjusted, %




60.8 (1.6) 61.5 (1.1) 67.3 (0.7) 66.1 (1.1) 65.2 (2.5) 61.9 (3.8) ―
Prevalence ratios
Model 1 0.95 (0.89 to 1.01) 0.93 (0.88 to 0.99) 1.00 0.94 (0.90 to 0.99) 0.86 (0.77 to 0.97) 0.84 (0.69 to 1.02) 0.003
Model 2 0.91 (0.87 to 0.96) 0.92 (0.88 to 0.96) 1.00 0.96 (0.91 to 1.01) 0.91 (0.84 to 0.99) 0.89 (0.77 to 1.02) 0.001
Model 3 0.97 (0.92 to 1.02) 0.96 (0.92 to 1.01) 1.00 0.95 (0.91 to 1.00) 0.87 (0.81 to 0.94) 0.88 (0.76 to 1.01) 0.001
Model 4 1.03 (0.98 to 1.09) 0.97 (0.92 to 1.03) 1.00 0.94 (0.90 to 0.99) 0.83 (0.75 to 0.93) 0.89 (0.74 to 1.08) <0.001
Men
n 606 992 1043 923 123 59
Prevalence,
unadjusted, %




46.4 (2.0) 51.5 (1.5) 55.0 (1.2) 51.9 (1.4) 50.8 (5.4) 51.4 (5.0) ―
Prevalence ratios
Model 1 0.92 (0.81 to 1.04) 0.97 (0.87 to 1.09) 1.00 0.91 (0.83 to 1.00) 0.71 (0.51 to 0.98) 0.80 (0.56 to 1.13) 0.041
Model 2 0.86 (0.77 to 0.95) 0.93 (0.85 to 1.01) 1.00 0.91 (0.84 to 0.99) 0.83 (0.66 to 1.05) 0.95 (0.74 to 1.21) 0.034
Model 3 0.91 (0.82 to 1.02) 0.95 (0.88 to 1.04) 1.00 0.92 (0.86 to 0.99) 0.86 (0.69 to 1.07) 1.00 (0.79 to 1.26) 0.177
Model 4 1.02 (0.90 to 1.15) 1.00 (0.89 to 1.11) 1.00 0.92 (0.83 to 1.01) 0.72 (0.53 to 0.98) 0.91 (0.66 to 1.25) 0.049
Women
n 624 929 1131 1011 181 68
Prevalence,
unadjusted, %




73.2 (1.7) 72.5 (1.1) 77.9 (0.6) 76.7 (0.9) 73.6 (1.9) 69.2 (5.6) ―
Prevalence ratios
Model 1 0.97 (0.93 to 1.02) 0.93 (0.88 to 0.98) 1.00 0.94 (0.90 to 0.98) 0.88 (0.78 to 0.99) 0.82 (0.65 to 1.03) 0.002
Model 2 0.95 (0.91 to 1.00) 0.93 (0.89 to 0.98) 1.00 0.96 (0.92 to 1.01) 0.89 (0.83 to 0.96) 0.83 (0.71 to 0.97) <0.001
Model 3 1.00 (0.95 to 1.04) 0.95 (0.91 to 1.00) 1.00 0.97 (0.92 to 1.01) 0.89 (0.83 to 0.96) 0.86 (0.73 to 1.02) 0.001
Model 4 1.04 (0.99 to 1.09) 0.95 (0.91 to 1.00) 1.00 0.96 (0.92 to 0.99) 0.87 (0.78 to 0.98) 0.90 (0.72 to 1.13) <0.001
Model 1 is unadjusted. Model 2 is adjusted for age. Model 3 is adjusted for age; sex; race or ethnicity; educational status; leisure-time physical activity; body mass index; and histories of
arthritis, cancer, chronic obstructive pulmonary disease, liver condition, thyroid problems, and sleep disorders. Model 4 is adjusted for all variables in Model 3 except age.
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risk equations for cardiovascular disease risk assessment,
self-reported sleep duration was related to predicted 10-year
cardiovascular risk in a nonlinear fashion: Risk was lowest
among adults who reported sleeping 7 hours per night and
increased as sleep duration lessened or lengthened. These
results help identify adults who are at increased risk of
cardiovascular disease and who could benefit from interven-
tions to improve their cardiovascular health.
Although previous investigations have presented data
about cardiovascular risk factors and sleep duration, these
studies apparently have not examined the association
between sleep duration and predicted cardiovascular risk.
Other studies, however, have examined associations between
sleep duration and various cardiovascular risk factors
included in the risk equations2–13; of note, sleep duration
was self-reported in all of these studies. These studies divided
sleep duration into 3 to 7 categories, with most studies using
5 categories. The reference category was typically 7 or
8 hours of sleep. These studies found no associations, linear
associations, and nonlinear associations between sleep
duration and the cardiovascular risk factors.
Of the risk factors that are part of the risk equation,
concentrations of total cholesterol varied little as a function of
sleep-duration categories and consequently had little effect on
differences in cardiovascular risk among categories of sleep
duration. The remaining factors were all significantly or nearly
significantly associated with sleep duration, mostly in a
nonlinear fashion, and contributed to the differences in
predicted cardiovascular risk among the sleep-duration cate-
gories, suggesting that improving cardiovascular health among
short and long sleepers requires a broad-based approach to
risk-factor modification. Of note were the high percentages of
current smokers among adults who reported sleeping
≤5 hours per night (32%) and ≥10 hours per night (38%)
compared with 17% of adults who reported sleeping 7 or
8 hours per night. Cigarette smoking is a stimulant that is
associated with difficulties in initiating the sleep cycle,
maintaining sleep, and waking up.17–19 Consequently, pre-
dicted cardiovascular risk could be lowered potentially among
those who reported sleeping ≤5 hours and ≥10 hours per night
by aggressively implementing smoking-cessation measures.
Strengths of the present study include a nationally
representative sample of US adults and the use of recently
released equations to estimate predicted 10-year cardiovas-
cular risk. Several limitations merit consideration. First, the
cross-sectional design of this study precludes concluding that
optimizing sleep duration could result in an improvement in
cardiovascular risk; however, the results of this study indicate
that risk factors for cardiovascular disease in adults who are
short sleepers and long sleepers warrant attention. Second,
sleep duration was obtained by self-report. Unfortunately,
information to validate these measures with polysomnography
or actigraphy was not available. Although limited information
is available about the validity and reliability of simple self-
reported questions about sleep duration,8,20–24 similar ques-
tions have been used routinely in numerous studies, espe-
cially large-scale epidemiological ones. Third, the percentage
of adults who reported sleeping ≥10 hours per night was
small, making the conduct of analyses of sleep duration
beyond 10 hours unfeasible. Fourth, cardiovascular disease
was also self-reported, and it is conceivable that participants
with subclinical disease and some participants with prevalent
disease were included in the analyses. Fifth, although this
analysis controlled for a sizeable number of potential
confounders, the possibility remains that the results are
subject to residual confounding.
In conclusion, self-reported sleep duration was associated
with predicted 10-year cardiovascular risk among adults aged
40 to 79 years who were free of self-reported cardiovascular
disease. These results are consistent with previous studies
that have shown that sleep duration predicts cardiovascular
morbidity and mortality and suggest that measures to improve





1. Cappuccio FP, Cooper D, D’Elia L, Strazzullo P, Miller MA. Sleep duration
predicts cardiovascular outcomes: a systematic review and meta-analysis of
prospective studies. Eur Heart J. 2011;32:1484–1492.
2. Heslop P, Smith GD, Metcalfe C, Macleod J, Hart C. Sleep duration and
mortality: the effect of short or long sleep duration on cardiovascular and all-
cause mortality in working men and women. Sleep Med. 2002;3:305–314.
3. Ayas NT, White DP, Manson JE, Stampfer MJ, Speizer FE, Malhotra A, Hu FB. A
prospective study of sleep duration and coronary heart disease in women.
Arch Intern Med. 2003;163:205–209.
4. Amagai Y, Ishikawa S, Gotoh T, Doi Y, Kayaba K, Nakamura Y, Kajii E. Sleep
duration and mortality in Japan: the Jichi Medical School Cohort Study. J
Epidemiol. 2004;14:124–128.
5. Lan TY, Lan TH, Wen CP, Lin YH, Chuang YL. Nighttime sleep, Chinese
afternoon nap, and mortality in the elderly. Sleep. 2007;30:1105–1110.
6. Ferrie JE, Shipley MJ, Cappuccio FP, Brunner E, Miller MA, Kumari M, Marmot
MG. A prospective study of change in sleep duration: associations with
mortality in the Whitehall II cohort. Sleep. 2007;30:1659–1666.
7. Meisinger C, Heier M, Lowel H, Schneider A, Doring A. Sleep duration and
sleep complaints and risk of myocardial infarction in middle-aged men and
women from the general population: the MONICA/KORA Augsburg cohort
study. Sleep. 2007;30:1121–1127.
8. Chen JC, Brunner RL, Ren H, Wassertheil-Smoller S, Larson JC, Levine DW,
Allison M, Naughton MJ, Stefanick ML. Sleep duration and risk of ischemic
stroke in postmenopausal women. Stroke. 2008;39:3185–3192.
9. Shankar A, Koh WP, Yuan JM, Lee HP, Yu MC. Sleep duration and coronary
heart disease mortality among Chinese adults in Singapore: a population-
based cohort study. Am J Epidemiol. 2008;168:1367–1373.
10. Ikehara S, Iso H, Date C, Kikuchi S, Watanabe Y, Wada Y, Inaba Y, Tamakoshi
A. Association of sleep duration with mortality from cardiovascular disease
and other causes for Japanese men and women: the JACC study. Sleep.
2009;32:295–301.
11. Suzuki E, Yorifuji T, Ueshima K, Takao S, Sugiyama M, Ohta T, Ishikawa-Takata
K, Doi H. Sleep duration, sleep quality and cardiovascular disease mortality
DOI: 10.1161/JAHA.114.001454 Journal of the American Heart Association 7















among the elderly: a population-based cohort study. Prev Med. 2009;49:135–
141.
12. Chien KL, Chen PC, Hsu HC, Su TC, Sung FC, Chen MF, Lee YT. Habitual
sleep duration and insomnia and the risk of cardiovascular events and all-
cause death: report from a community-based cohort. Sleep. 2010;33:177–
184.
13. Kim Y, Wilkens LR, Schembre SM, Henderson BE, Kolonel LN, Goodman MT.
Insufficient and excessive amounts of sleep increase the risk of premature
death from cardiovascular and other diseases: the Multiethnic Cohort Study.
Prev Med. 2013;57:377–385.
14. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R,
Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson J, Schwartz JS,
Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW. 2013 ACC/AHA
guideline on the assessment of cardiovascular risk: a Report of the American
College of Cardiology/American Heart Association task force on practice
guidelines. Circulation. 2014;129:S49–S73.
15. Centers for Disease Control and Prevention. About the National Health and
Nutrition Examination Survey. Available from: http://www.cdc.gov/nchs/
nhanes/about_nhanes.htm. Accessed March 18, 2011.
16. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status,
and future directions. Circulation. 2010;121:1768–1777.
17. Wetter DW, Young TB. The relation between cigarette smoking and sleep
disturbance. Prev Med. 1994;23:328–334.
18. Phillips BA, Danner FJ. Cigarette smoking and sleep disturbance. Arch Intern
Med. 1995;155:734–737.
19. Jaehne A, Unbehaun T, Feige B, Lutz UC, Batra A, Riemann D. How smoking
affects sleep: a polysomnographical analysis. Sleep Med. 2012;13:1286–1292.
20. Patel SR, Ayas NT, Malhotra MR, White DP, Schernhammer ES, Speizer FE,
Stampfer MJ, Hu FB. A prospective study of sleep duration and mortality risk in
women. Sleep. 2004;27:440–444.
21. Lockley SW, Skene DJ, Arendt J. Comparison between subjective and
actigraphic measurement of sleep and sleep rhythms. J Sleep Res.
1999;8:175–183.
22. Levine DW, Kripke DF, Kaplan RM, Lewis MA, Naughton MJ, Bowen DJ,
Shumaker SA. Reliability and validity of the Women’s Health Initiative Insomnia
Rating Scale. Psychol Assess. 2003;15:137–148.
23. Signal TL, Gale J, Gander PH. Sleep measurement in flight crew: comparing
actigraphic and subjective estimates to polysomnography. Aviat Space Environ
Med. 2005;76:1058–1063.
24. Girschik J, Heyworth J, Fritschi L. Reliability of a sleep quality questionnaire for
use in epidemiologic studies. J Epidemiol. 2012;22:244–250.
DOI: 10.1161/JAHA.114.001454 Journal of the American Heart Association 8
Sleep Duration and Cardiovascular Risk Ford
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
